Abilify Lawsuits

Background information on Abilify lawsuits, settlements and litigation updates published between 2016 to 2019.

Abilify Lawsuit Overview

The Abilify litigation involved claims that the popular antipsychotic medication aripiprazole caused compulsive gambling and other uncontrollable behaviors in users. Manufactured by Bristol-Myers Squibb and Otsuka Pharmaceutical, Abilify was widely prescribed for schizophrenia, bipolar disorder, and depression. However, thousands of patients later alleged that the drug’s dopamine-modulating effects led to destructive impulses such as pathological gambling, hypersexuality, and compulsive shopping, resulting in severe financial and emotional harm.

However, thousands of patients later alleged that the drug’s dopamine-modulating effects led to destructive impulses such as pathological gambling, hypersexuality, and compulsive shopping, resulting in severe financial and emotional harm.

As reports accumulated, lawsuits were filed across the country accusing the drug makers of failing to warn doctors and consumers about these behavioral side effects. The cases were consolidated in multidistrict litigation (MDL No. 2734) in the U.S. District Court for the Northern District of Florida, where evidence revealed that early signals of impulse-control problems had surfaced years before the manufacturers updated the warning label. Plaintiffs argued that the companies prioritized profits over safety while marketing Abilify as a stable, low-risk treatment option.

After several years of coordinated discovery and bellwether proceedings, the majority of Abilify lawsuits were resolved through confidential settlements in 2019. The litigation brought national attention to the link between psychiatric medications and impulse-control disorders.

Abilify Litigation Updates

December 9, 2019: Final Abilify Settlement Announced, Ending Litigation

A final nationwide settlement was reached to resolve all remaining Abilify gambling addiction lawsuits. The agreement brought closure to years of litigation involving claims that Bristol Myers Squibb and Otsuka Pharmaceuticals failed to warn patients about the drug’s risk of compulsive behaviors. The resolution marked the official end of coordinated federal and state proceedings.

November 12, 2019: Remaining Abilify Cases Fast-Tracked for Final Resolution

Judge M. Casey Rodgers ordered that all remaining Abilify lawsuits be expedited for closure, requiring settlement confirmation or dismissal filings. The directive ensured efficient completion of the multidistrict litigation following the global settlement agreement.

October 2, 2019: Abilify Cases Remanded for Closure in Federal Courts

The MDL court remanded unresolved Abilify lawsuits back to their original jurisdictions for final resolution. The move reflected the conclusion of centralized pretrial proceedings and the near completion of all outstanding claims.

August 28, 2019: Final Group of Abilify Cases Selected for Resolution

Judge Rodgers identified the last group of Abilify cases to be prepared for remand or administrative closure. The selection represented the final stage of case management within the multidistrict litigation.

June 21, 2019: Second Abilify Trial Pool Officially Selected

A second bellwether trial pool was finalized for remaining plaintiffs who had not settled their cases. The move maintained trial readiness as negotiations continued following the earlier global settlement.

May 14, 2019: Second Abilify Bellwether Pool Proposed

The court proposed an additional group of representative cases that could proceed to trial if remaining claims were not resolved. The proposal helped maintain momentum toward closure and ensured equitable handling of unresolved lawsuits.

April 26, 2019: Abilify Settlement Talks Continue in State Courts

After the global federal settlement, ongoing negotiations in state courts aimed to finalize compensation structures and administrative procedures for claimants not included in the MDL agreement. Attorneys reported continued progress toward a complete resolution.

March 19, 2019: New Jersey Multicounty Litigation Established for Abilify Claims

New Jersey’s Supreme Court approved centralized management for Abilify gambling lawsuits filed in state court. The MCL ensured consistent rulings and discovery procedures, mirroring the coordination achieved in the federal MDL.

February 26, 2019: Global Abilify Settlement Reached Over Gambling Losses

Bristol Myers Squibb and Otsuka agreed to a global settlement resolving thousands of lawsuits from patients who developed compulsive gambling, shopping, and sexual behaviors while taking Abilify. The agreement provided compensation for financial and emotional harm, marking a major milestone in the litigation.

November 2, 2018: Bellwether Settlements Reached in Abilify MDL

Several early bellwether cases were settled confidentially before trial, signaling meaningful progress toward a broader resolution. The settlements avoided the risk of unpredictable jury verdicts and set the stage for nationwide negotiations.

October 22, 2018: Abilify Settlement Meeting Scheduled

Judge Rodgers ordered attorneys for both sides to attend a court-supervised settlement conference to explore a global resolution. The directive came as the first bellwether trials approached, emphasizing judicial pressure for compromise.

August 23, 2018: Bellwether Cases Selected for Abilify Gambling MDL

The court selected representative Abilify cases to serve as bellwether trials, each involving plaintiffs with severe gambling-related losses. The selection process was designed to test liability and damages issues that would influence broader settlement discussions.

June 26, 2018: Summary Judgment Denied in Abilify Gambling MDL

Judge Rodgers denied summary judgment motions filed by Bristol Myers Squibb and Otsuka, finding that plaintiffs had presented sufficient expert evidence to allow their claims to proceed to trial. The ruling kept the first bellwether trials on track.

June 12, 2018: Abilify Centralization Established in New Jersey State Court

The New Jersey judiciary approved the creation of a multicounty litigation for state-level Abilify gambling lawsuits. The coordination ensured efficiency and consistency in cases proceeding outside of the federal MDL.

May 31, 2018: First Federal Abilify Gambling Trial Set for June 2018

The first bellwether trial in the federal Abilify MDL was scheduled to begin in June 2018, focusing on allegations that the antipsychotic’s dopamine activity caused compulsive gambling and other impulsive behaviors. The trial was intended to guide future case valuations.

March 12, 2018: Defendants Seek Summary Judgment in Abilify Gambling Lawsuits

Drug manufacturers filed motions for summary judgment arguing that plaintiffs lacked scientific proof of causation between Abilify and compulsive gambling. Plaintiffs countered with expert testimony and internal company data suggesting the companies knew of the behavioral risks.

January 9, 2018: Abilify Gambling Lawsuits Move Toward First Trials

Discovery and expert depositions concluded in preparation for the first wave of bellwether trials. Both sides finalized witness lists and trial exhibits as the MDL neared its first jury proceedings.

December 8, 2017: Judge Orders Production of Internal Abilify Documents

The court compelled defendants to turn over additional internal records related to marketing, drug safety, and post-market surveillance. Plaintiffs alleged that the companies withheld critical evidence about impulse-control risks for years.

September 6, 2017: Settlement Master Appointed in Abilify Gambling Lawsuits

Judge Rodgers appointed a settlement master to oversee negotiations between plaintiffs and the drug manufacturers. The move indicated growing judicial encouragement to reach a global resolution before trial.

July 31, 2017: Abilify Compulsive Gambling Cases Prepared for Trial

The court identified several bellwether plaintiffs whose cases would be the first to go before juries. Attorneys began trial preparations focused on establishing the causal link between Abilify and compulsive behavior.

April 20, 2017: “Science Day” Reviews Abilify Gambling Addiction Evidence

Experts presented scientific data on dopamine activity and impulse-control mechanisms during a Science Day session in the MDL. The hearing provided the court with context on how Abilify might trigger compulsive behaviors such as gambling and shopping.

March 2, 2017: Direct Filing Approved for Abilify MDL Cases

The MDL judge authorized direct filing of new Abilify lawsuits in the Northern District of Florida, allowing plaintiffs nationwide to bypass transfer delays. The streamlined process accelerated case intake as litigation expanded.

February 7, 2017: Attorneys Seek Leadership Roles in Abilify MDL

Lawyers representing plaintiffs in the consolidated litigation applied for leadership appointments to coordinate discovery and settlement efforts. The leadership team was expected to unify legal strategy across hundreds of cases.

January 25, 2017: Case Management Order Entered in Abilify MDL

Judge Rodgers issued the first comprehensive case management order, establishing pretrial deadlines, confidentiality procedures, and expert disclosure rules to guide the growing federal litigation.

December 15, 2016: Abilify Gambling Cases Continue Mounting Nationwide

Following MDL consolidation, hundreds of new lawsuits were filed across the U.S. by individuals who said Abilify caused them to lose large sums through compulsive gambling. Attorneys predicted the litigation would rival other major pharmaceutical mass torts.

December 8, 2016: Abilify Gambling Lawsuits Centralized in Federal MDL

The Judicial Panel on Multidistrict Litigation transferred all federal Abilify lawsuits to the Northern District of Florida before Judge M. Casey Rodgers. The consolidation unified pretrial proceedings for cases alleging gambling and impulse-control side effects.

October 3, 2016: Motion Filed to Centralize Abilify Gambling Lawsuits in MDL

Attorneys petitioned the Judicial Panel on Multidistrict Litigation to consolidate growing Abilify gambling claims. The motion cited overlapping allegations that the antipsychotic’s design and labeling failed to warn about addiction risks.

May 6, 2016: New Jersey Lawsuits Filed Over Abilify Gambling Side Effects

The first lawsuits were filed in New Jersey state courts alleging that Abilify caused users to develop compulsive gambling habits. Plaintiffs claimed that the manufacturers ignored warning signs and failed to update the drug’s label to reflect the serious behavioral side effects.

Abilify Lawsuit Examples

February 26, 2016: Abilify Gambling Lawsuit Filed Over Uncontrollable Urges

A Florida man filed a lawsuit alleging that Abilify caused him to develop a gambling addiction that resulted in significant financial losses. The complaint accused Bristol Myers Squibb and Otsuka Pharmaceuticals of failing to warn about the drug’s impulse-control side effects. The case reflected the first wave of personal injury claims over the antipsychotic’s behavioral risks.

March 10, 2016: Second Abilify Gambling Lawsuit Filed by Louisiana Woman

A Louisiana woman filed suit after losing thousands of dollars through compulsive gambling that began shortly after she started taking Abilify. Her complaint claimed the drug’s dopamine effects led to addictive behavior and that the manufacturer ignored mounting evidence linking the drug to impulse-control problems.

April 14, 2016: Abilify Gambling Injury Lawsuit Seeks Compensation for Financial Losses

Another plaintiff came forward alleging that Abilify caused him to develop compulsive gambling behaviors that destroyed his savings and strained personal relationships. The lawsuit alleged the companies failed to act on clinical data and post-market reports documenting the drug’s side effects.

May 10, 2016: Abilify Impulsivity Lawsuits Continue to Grow Nationwide

Courts saw a steady increase in Abilify lawsuits filed by patients who developed gambling, shopping, and sexual addictions while taking the medication. Plaintiffs accused the drugmakers of concealing side effect information from doctors and patients for years to protect sales. The expanding litigation signaled a potential multidistrict proceeding.

August 15, 2016: Abilify Gambling Losses Allegedly Caused Financial Ruin and Marital Breakdown

A married couple filed a lawsuit after the husband’s compulsive gambling, allegedly triggered by Abilify, led to bankruptcy and the collapse of their marriage. The complaint claimed the manufacturers knew of similar reports from clinical trials but withheld them from U.S. regulators and prescribers.

September 12, 2016: Third Abilify Gambling Lawsuit Filed Over Compulsive Behavior

A California woman filed suit alleging that Abilify caused her to engage in uncontrollable gambling and reckless spending. The complaint argued that the drug’s label failed to include adequate warnings about the potential for impulse-control disorders despite years of international safety data.

November 18, 2016: Compulsive Gambling Side Effects Lead to Additional Abilify Lawsuits

Multiple new lawsuits were filed against Bristol Myers Squibb and Otsuka alleging that patients experienced compulsive gambling after taking Abilify. Plaintiffs said they were never warned of the risk of uncontrollable urges, and many reported devastating financial consequences.

December 21, 2016: Abilify Compulsive Gambling Lawsuit Filed Over Life Savings Lost

A man filed a lawsuit claiming he lost his retirement savings as a result of compulsive gambling that began after starting Abilify. The complaint alleged the manufacturers prioritized profits over safety and ignored mounting adverse event reports linking the drug to addictive behavior.

January 24, 2017: Abilify Gambling Warning Lawsuit Alleges Failure to Disclose Risks

Another lawsuit accused the manufacturers of failing to update Abilify’s warning label in a timely manner after evidence of gambling addiction surfaced. The plaintiff claimed the companies knew of the behavioral side effects but delayed adding the risk to the label to preserve market share.

February 8, 2017: Abilify Lawsuit Cites FDA Adverse Event Reports of Gambling Problems

A lawsuit filed in federal court referenced hundreds of FDA adverse event reports describing gambling and other compulsive behaviors among Abilify users. The complaint argued that the companies’ failure to warn patients directly led to widespread financial harm and emotional distress.

Abilify Research and Reports

February 23, 2015: Study Links Abilify to Impulse-Control Disorders

Medical researchers identified a strong association between Abilify and the development of impulse-control disorders, including compulsive gambling, shopping, and binge eating. The findings supported growing anecdotal reports from patients who described uncontrollable urges after starting the antipsychotic. The study prompted calls for stronger warnings and further investigation into dopamine-related side effects.

November 17, 2015: Canada Updates Abilify Label to Include Compulsive Behavior Risks

Health Canada announced new label warnings for Abilify and similar antipsychotics, citing evidence that the drugs could cause pathological gambling and other compulsive behaviors. The agency’s action came after numerous international case reports describing sudden behavioral changes. The update preceded similar safety reviews in the United States.

May 3, 2016: FDA Issues Warning About Abilify Gambling and Impulse Problems

The U.S. Food and Drug Administration released a safety communication warning that Abilify may cause uncontrollable urges to gamble, eat, shop, or engage in risky sexual activity. The agency advised prescribers to monitor for behavioral changes and discontinue treatment if compulsive behaviors emerged. The warning marked the first official federal acknowledgment of the problem.

March 27, 2017: Study Confirms Link Between Abilify and Compulsive Gambling

A large observational study reinforced prior evidence connecting Abilify to gambling addiction and other impulse-control issues. Researchers found that patients taking the drug were significantly more likely to develop compulsive behaviors than those on other antipsychotics. The results supported the FDA’s earlier warning and further validated patient lawsuits.

May 22, 2017: ISMP Report Highlights Antipsychotic Risk Profiles

The Institute for Safe Medication Practices released a quarterly report identifying Abilify as one of the leading antipsychotic drugs associated with impulse-control disorder reports. The analysis of FDA adverse event data revealed a clear pattern of gambling and compulsive spending linked to the medication. The group urged heightened physician awareness and patient screening.

March 13, 2018: Study Finds Abilify Ineffective for Treating Depression in Some Patients

A new analysis of clinical data questioned the effectiveness of Abilify as an adjunct treatment for major depressive disorder. Researchers found limited benefit compared to placebo, while patients continued to face heightened risks of side effects such as restlessness and compulsive behaviors. The findings reignited debate over the drug’s broad off-label use.

April 10, 2018: Case Study Highlights Severe Abilify Side Effects in Individual Patient

A published case study detailed an instance of a patient developing compulsive gambling behavior after being prescribed Abilify for bipolar disorder. The patient’s symptoms resolved shortly after discontinuing the medication, reinforcing prior research linking dopamine receptor activity to impulse-control disturbances.

August 14, 2019: Public Citizen Urges Stronger Warnings for Parkinson’s and Antipsychotic Drugs

The consumer advocacy group Public Citizen petitioned the FDA to issue stronger black box warnings for dopamine agonists and antipsychotic drugs, including Abilify. The petition cited numerous cases of gambling addiction and other behavioral side effects, arguing that existing warnings failed to adequately alert patients to the risks.